South African healthcare CFOs are operating in a system where demand remains high, but financial pressure is becoming harder to absorb. The issue is not one single cost line or one policy change, but the combination of funding imbalance, staffing shortages, patient affordability pressure, medical inflation, reimbursement complexity, medicine costs, financial leakage, and fragmented visibility.

South Africa spends around 8.1% of its GDP on health care, amounting to roughly US$499 per capita.1 At the same time, to fully fund the proposed National Health Insurance framework, the National Department of Health estimates it will need to raise an additional R200 billion per year.2 These figures point to a strained healthcare system where the financial pressure is already visible before any new operating model is fully resolved.

For healthcare CFOs, the question is not only how much the sector spends. Instead, the more practical question is whether their organization can see where cost, revenue, cash, and risk are moving. A hospital group, clinic network, specialist practice, senior care provider, mental health organization, or home care provider cannot manage margin only through top-line reporting, they also need visibility by site, payer, service line, patient group, staffing model, pharmacy cost, claim status, and collection pattern.

The finance function is therefore becoming the control room. CFOs are expected to help boards understand which services are sustainable, where labour cost is eroding margin, which payer relationships are profitable, where patient debt is rising, and which operational risks could become financial exposure. That requires faster reporting, stronger controls, and a more connected view of the business.

This whitepaper sets out the nine pressure points South African healthcare CFOs should be watching, and what each one means for financial planning, reporting, margin protection, and board-level decision-making.

1. South Africa’s healthcare funding imbalance

South Africa’s healthcare funding environment is uneven. Approximately 51% of total health expenditure is consumed by only 14% of the population, leaving the remaining 84% to 86% of the population to rely on the remaining 49% of funds.3 Private sector healthcare spending accounts for 4.2% of GDP while serving a minority, whereas public sector healthcare spending is 4.4% of GDP while serving the vast majority of citizens.4

For CFOs in private healthcare organizations, this imbalance is not a distant policy issue, it shapes the market in which they operate. Public sector constraints affect patient movement, affordability expectations, service demand, referral behaviour, and the wider political pressure around healthcare access. Private providers may operate commercially, but they do not operate in isolation from the public system.

The financial implication CFOs need to understand is how system-wide pressure may affect their own payer mix and patient volumes. A provider may see more demand, but not all demand is financially equal. Some patient groups may carry higher collection risk. Some services may be clinically necessary but financially difficult to sustain. Some sites may appear busy while still underperforming because the cost to serve is not properly visible.

This is where healthcare finance teams need to move beyond consolidated reporting. The CFO needs to know which parts of the organization are absorbing pressure from the wider system, and whether that pressure is being recovered through reliable revenue.

The planning question becomes: if the healthcare system remains financially imbalanced, which parts of the organization are most exposed to patient affordability pressure, tariff pressure, payer movement, or demand that does not translate into sustainable margin?

2. Labour as the largest pressure point

Healthcare is a labour-intensive sector. When staffing pressure increases, the financial effect is immediate. By the year 2030, South Africa is projected to face a massive shortfall of approximately 97,000 healthcare workers across all categories.5 Provincial departments of health already spend approximately 65% of their total expenditure on wages, creating severe fiscal ceilings for staffing and operational budgets.4

The private sector faces its own version of this problem. Clinical staff shortages can drive wage pressure, overtime, locum use, agency staffing, retention payments, and recruitment costs. These costs do not sit neatly in one budget line. They affect patient throughput, theatre utilization, bed availability, service quality, and the organization’s ability to grow.

For the CFO, labour is not only an HR matter, it’s a margin and capacity issue. A site can have strong patient demand but weak financial performance if staffing costs are too high for the revenue it generates. A service line can look strategic but become difficult to sustain if it relies too heavily on scarce clinical skills, overtime, or high-cost temporary staff.

The financial problem is often made worse by delayed reporting. If labour costs are reviewed only at month-end, and not linked to patient volumes or service output, the organization sees the problem too late. Finance may know that payroll is high, but not whether it is high because of inefficiency, underpricing, staffing shortages, poor scheduling, or genuine demand growth.

Healthcare CFOs need reporting that links labour cost to patient activity. That means labour cost per patient, labour cost per episode, overtime by site, agency spend by service line, and margin after staffing cost. Without that level of visibility, workforce planning becomes reactive, and staffing pressure quietly erodes profitability.

3. Patient affordability and bad debt risk

Patient affordability is becoming a cash-flow issue for healthcare organizations. Out-of-pocket expenses incurred by insured medical scheme members increased by 7.9% from 2013 to 2019, making up 18.1% of the total amount claimed.5 In the wider population, 84% of South Africans who lack medical aid coverage cite unaffordability as the primary reason, and 49% of citizens report going without necessary medicine or medical treatment at least once in the past year.6

This matters because billed revenue and collected revenue are not the same. Healthcare organizations may perform the service, issue the invoice, and recognize the revenue, but still face delayed collections, co-payment disputes, shortfalls, write-offs, or bad debt. As patients face more affordability pressure, the revenue cycle becomes more exposed.

For CFOs, this creates a need to distinguish between revenue growth and revenue quality. A growing patient base can still weaken working capital if more patients are struggling to pay co-payments or settle balances. A service line can appear strong on billing but perform poorly once rejected claims, short payments, and collection delays are included.

Patient affordability also affects demand behaviour. Patients may delay treatment, downgrade cover, avoid follow-up visits, or shift to lower-cost options. This can affect patient volumes, case mix, and the timing of revenue. It can also create operational pressure when patients arrive later in their care journey with more complex needs.

The CFO’s job is to make this visible. The finance team should track co-payment collection rates, debtor days by patient category, write-offs by site, patient shortfalls by service type, and payer mix movement. The aim is to not only manage collections more tightly but to understand when affordability pressure is changing the economics of care.

A healthcare organization that does not monitor patient affordability as a financial risk may overestimate its revenue resilience.

4. Medical inflation and rising cost of care

Worldwide, medical inflation typically exceeds consumer price inflation by 3-4%.7 If current contribution inflation rates continue unchecked, it is estimated that middle-class households will spend up to a third of their total income on health insurance premiums by 2030.5

This creates a difficult position for providers. Their own input costs rise, but patients and funders may not be able or willing to absorb the full increase. Consumables, equipment, diagnostics, utilities, facility maintenance, technology, insurance, compliance, and supplier costs all affect the cost to serve. If reimbursement does not move at the same pace, margin comes under pressure.

The CFO’s challenge is that medical inflation rarely appears as one clean number. It appears in theatre consumables, pharmacy stock, maintenance contracts, diagnostic inputs, staffing cost, software subscriptions, laundry, security, facilities, and outsourced services. Each cost line may seem manageable on its own, but together they change the economics of delivery.

This is why cost-to-serve visibility matters. CFOs need to know how inflation affects each site and service line. A procedure may remain profitable in one location but become marginal in another. A supplier increase may be manageable for high-volume services but damaging for lower-volume specialist offerings. A facility cost increase may change the break-even point for a branch or clinic.

Medical inflation also affects patient affordability. If medical scheme contributions rise too quickly, patients may downgrade, reduce benefits, or carry higher out-of-pocket exposure. That means inflation affects both sides of the financial model: it raises provider cost and can weaken the patient’s ability to pay.

The CFO’s response should be more specific than just cost-cutting. Finance needs to isolate where costs are rising, whether they can be recovered, and whether the organisation has enough operational visibility to act before margin is lost.

5. Reimbursement, tariffs, and PMBs

Reimbursement is one of the clearest places where healthcare margin is made or lost. Prescribed Minimum Benefits legally mandate medical schemes to fully cover treatments for approximately 270 limited conditions and 26 chronic conditions, restricting payer margin controls.8 At the same time, benefit tiering leads to significant patient shortfalls on high-cost treatments. For example, a joint replacement costs an average of ZAR 40,000 per prosthesis, which is often not fully covered by lower-tier plans.5

For CFOs, this creates a practical revenue problem. The organization needs to understand what it costs to provide care, what the funder will reimburse, what the patient may need to pay, and how likely that amount is to be collected. The headline tariff is only one part of the picture.

Reimbursement pressure affects profitability in several ways. Claims may be rejected, delayed, partially paid, or challenged. PMB rules may affect what funders must cover and benefit limits may leave patients exposed. Tariff arrangements may not reflect the real cost of delivery. Administration errors may create avoidable leakage.

This means CFOs need payer-level profitability, not only payer-level revenue. A payer that brings high volumes may still produce weak margin if payment delays are long, rejection rates are high, or tariff gaps are wide. A service line that appears clinically important may need closer financial review if reimbursement does not cover the cost to serve.

The CFO should be asking direct questions: Which payers are profitable after rejection, collection, and admin cost? Which services have the largest gap between tariff and cost? Which patient shortfalls are most difficult to collect? Which claims fail because of coding, documentation, authorisation, or timing?

Without this view, healthcare organizations can grow revenue while weakening cash flow and margin. CFOs need reimbursement analytics that connect billing, claims, clinical activity, patient responsibility, and finance.

6. Pharmaceutical pricing and medicine margin control

Medicine cost is a working capital and margin issue. South Africa relies heavily on pharmaceutical imports, importing R44 billion worth of pharmaceutical goods in 2023, of which R31 billion was for measured doses of medicaments, exposing procurement to foreign exchange risks.9 To align with NHI structures, Single Exit Price legislation will shift; specifically, the logistic fees currently built into private sector pharmaceutical prices will be re-routed to fund NHI operations.5

For healthcare CFOs, pharmaceutical spend needs close attention because it combines procurement risk, pricing regulation, stock control, clinical demand, and reimbursement complexity. Medicine can tie up cash, create write-off risk, and expose the organization to supplier price movements or foreign exchange pressure.

The Single Exit Price environment also limits commercial flexibility. Where pricing is regulated and dispensing fees are constrained, providers cannot always rely on pricing adjustments to protect margin. That makes stock management, procurement discipline, usage monitoring, and margin visibility more important.

The finance risk is not only the cost of medicine purchased. It is the cost of stock held too long, stock written off, stock lost, stock billed incorrectly, or stock used in services where reimbursement does not fully cover the cost. Pharmacy visibility therefore, needs to connect procurement, stock, billing, claims, and clinical usage.

CFOs should also watch the timing of cash. Medicine procurement may require upfront payment or short supplier terms, while recovery from funders and patients may take longer. This creates working capital pressure, especially where high-cost medicine is involved.

A finance team that cannot see medicine margin by site, item, payer, and patient group will struggle to manage this pressure. The CFO needs to know where medicine cost is recoverable, where it is exposed, and where stock control weaknesses are creating hidden losses.

7. High-cost medicines and health technology decisions

Healthcare technology and high-cost treatments create difficult investment choices. The private sector has 12.21 functional operating theatres per 100,000 people, compared to just 1.95 per 100,000 in the public sector, highlighting massive disparities in surgical and health technology investments.10 South Africa lacks an advanced Health Technology Assessment body to cap medicine inflation; by comparison, the UK’s NHS uses NICE to evaluate new technologies and successfully caps medicine inflation at 2%.5

For CFOs, this is where clinical progress and financial exposure meet. New devices, diagnostics, biologics, targeted therapies, and surgical technologies can improve care, but they also raise questions about affordability, utilization, reimbursement, and long-term cost.

The organization may want to invest in a new diagnostic platform, theatre capability, treatment pathway, or specialist service. The clinical case may be strong; however, the financial case may still be uncertain. If utilization is lower than expected, reimbursement is delayed, funder approval is inconsistent, or patient shortfalls are high, the investment can place pressure on cash and margin.

This does not mean CFOs should block innovation. It means healthcare organizations need a disciplined financial review model. Before committing to high-cost medicine or technology, finance needs to understand demand, reimbursement probability, capital cost, maintenance cost, staff requirements, consumables, expected utilization, payer mix, and patient affordability.

The CFO also needs post-investment tracking. A technology investment that looked sound in the business case must be measured against actual usage, actual recovery, actual cost, and actual margin. Without that feedback loop, investment decisions become too dependent on assumptions.

High-cost care decisions should be treated as portfolio decisions. Some services may be strategically important even if margins are thin. Others may need tighter utilization rules, funder pre-approval, or revised pricing discussions. The CFO’s role is to make the financial trade-offs visible.

8. Fraud, waste, leakage, and financial control

Financial leakage is a direct threat to sustainability. The Section 59 investigation into medical aids revealed that private schemes engaged in irregular claims practices and unlawfully targeted certain doctors, resulting in over R30 billion in losses.3 A Competition Commission health market inquiry estimated that roughly half of all private-sector healthcare expenditure is either wasted or lost to fraud.3

For CFOs, fraud and waste should not be treated as abstract system issues. They show why controls matter. Leakage can come from billing errors, duplicate claims, procurement abuse, stock losses, weak authorization, poor segregation of duties, manual overrides, or incomplete audit trails.

In healthcare organizations, leakage is often difficult to see because the operating model is complex. Clinical activity, pharmacy stock, supplier purchasing, patient billing, claims submission, and finance reporting may all sit in different systems. If those systems do not reconcile cleanly, the CFO may only see the financial effect after the loss has already occurred.

This is why finance controls need to be built into daily operations, not only month-end review. Approval workflows, claims checks, stock controls, procurement rules, exception reports, and audit trails need to be visible and reliable. The CFO should be able to see where manual intervention is happening and whether it is justified.

Waste also deserves attention. Not every loss is fraud. Some losses come from inefficient processes, unnecessary duplication, over-servicing, poor stock rotation, delayed billing, or preventable claim rejection. These issues can become material when margins are tight.

The finance function needs to identify leakage early. That requires exception reporting, stronger reconciliations, clearer approval controls, and better links between operational activity and financial outcomes.

9. The CFO visibility framework

The final question for healthcare CFOs is what they need to measure. In the public sector, a lack of operational control and clinical visibility has driven an exponential rise in medico-legal claims, which ballooned from R28.6 billion in 2015 to R80.4 billion in 2018.4 In terms of digital visibility, real-world evidence platforms in the private sector are advancing rapidly, with companies like Kapsule processing structured, de-identified health records for over 75 million patients across 14 African countries.11

The lesson for CFOs is that visibility is no longer optional. Financial exposure often starts outside the finance department. It starts in patient flow, clinical documentation, staffing, procurement, authorization, billing, stock usage, or claims processing. By the time finance sees it in the ledger, the organization may already have lost the opportunity to act.

A CFO visibility framework should connect six areas.

First, margin visibility. Finance should be able to see margin by site, payer, service line, patient group, and procedure. This helps identify which areas are profitable, which are subsidized, and which need operational review.

Second, labour visibility. CFOs need labour cost per patient or episode, overtime trends, agency spend, vacancy impact, and staffing cost by site or service line.

Third, revenue quality. Finance should track claims rejection, delayed payment, patient shortfalls, co-payment collections, bad debt, debtor days, and payer-level profitability.

Fourth, medicine and supplier cost. CFOs need visibility into stock values, write-offs, pharmacy margin, supplier increases, high-cost medicine usage, and procurement exceptions.

Fifth, compliance and control. Finance teams should track audit findings, missing evidence, manual overrides, approval exceptions, reconciliation delays, and reporting gaps.

Sixth, board reporting. The CFO needs a reporting pack that shows not only what happened, but why it happened and what management is doing about it.

This visibility framework is what allows finance to move from delayed reporting to active control. The aim is not to create more reports, but to give leadership a reliable view of where the organization is making money, where margin is leaking, where risk is building, and where decisions are needed.

Conclusion

South African healthcare CFOs are working in a sector where financial pressure is coming from many directions at once. Funding imbalance affects the wider system. Labour shortages raise costs and constrain capacity. Patient affordability weakens cash recovery. Medical inflation increases the cost to serve. Reimbursement complexity affects revenue quality. Medicine costs create working capital pressure. High-cost technology decisions need tighter financial review. Fraud, waste, and leakage reduce sustainability.

The common thread is visibility. CFOs cannot manage these pressures with delayed closes, spreadsheet-heavy reporting, and disconnected systems. They need to connect clinical activity, staffing, procurement, pharmacy, billing, claims, and finance into one operating view.

The healthcare CFO cannot control every external pressure. They cannot stop wage inflation, change patient affordability overnight, or force funders to pay more, but they can control how quickly the organization sees risk, how accurately it understands margin, and how confidently it makes financial decisions.

The strongest healthcare finance teams will be those that can show the board where cost is rising, where revenue is weakening, where cash is trapped, where controls are failing, and where growth is still financially sustainable.

That is the CFO’s margin agenda. It is not only about cutting costs, but it’s about building the financial visibility needed to protect care, support growth, and keep the organization financially steady in a system under pressure.

Footnotes

1. Wikipedia. (n.d.). Healthcare in South Africa. Wikipedia.

2. Moonstone Information Refinery. (2024, February 22.). How much tax you may have to pay to fund NHI. Moonstone Information Refinery.

3. Parliamentary Monitoring Group. (2025, October 28.). NHI Funding Models; Bridge Plan funding to sustain HIV prevention and treatment; Filling critical vacancies; with Ministry. PMG.

4. Institute for Economic Justice & SECTION27. (2019.). Funding the Right to Health. IEJ.

5. Clarke, M. (2025, February 20.). Question to the Minister of Health, NW198. PMG.

6. Mpako, A., & Ndoma, S. (2025, December 23.). South Africans lament government performance on improving basic health care. Afrobarometer.

7. Patel, V., Pastellides, C., Theologides, A., Collie, S., & Wayburne, L. (2025, July.). How healthy is our nation? Comparing disease prevalence among medical scheme members and the broader population in South Africa. Discovery.

8. Medical Aid Quotes. (n.d.). PMBs. Medical Aid Quotes.

9. Standard Bank. (2024, May 3.). How is healthcare activity in South Africa measured?. Standard Bank.

10. Dell, A.J., Kahn, D., & Klopper, J. (2018, June.). Surgical resources in South Africa: an analysis of the inequalities between the public and private sector. SciELO SA.

11. Kapsule Research Team. (2026, February 28.). South Africa’s Healthcare System: Public, Private, and Digital. Kapsule.